Feng Yuan Pharmaceutical (000153)
The company has signed a Joint Venture Contract with Anhui Zhongren Science and Technology Company to set up Anhui Feng Yuan Zhongren Pharmaceutical Company, which is engaged in the research and development, production and sales of new implantable drugs.
Ankebio (300009)
Cooperated with Hefei Medical and Industrial Pharmaceuticals on the transfer of production technology and new drug certificates and production approvals for Tegeo tablets. Tigio tablets, developed by Hefei Medical and Industrial Pharmaceuticals, received clinical approvals in 2007 and is currently undergoing clinical trials, and is expected to be ready for production and sales in 2012.
Pu Luo (000739)
The cancer gene-targeted diagnostic reagent developed by the company has high barrier characteristics. According to the information, the project is to use human genetic genomics technology to lock the cancer target, using cloned proteins or natural proteins as probes, carrying contrast agents, in the form of injections into the human body. It can be used as a basis for confirming the size of cancer cells and the need for drug treatment. In addition, Baxin, exclusively produced by Prosperity, is a new national class II anti-cancer drug. At present, Baxin has become the drug of choice for cancer treatment in county-level and above hospitals in Zhejiang Province, as well as large hospitals in Guangdong, Beijing, Jiangsu and other provinces, with annual sales reaching more than 80 million yuan.
Hengrui Medicine (600276)
The company's production of tigio capsule is a fluorouracil derivative oral anticancer agent, was formally approved at the end of August 2010, September has begun production. This year and next year will become the first-line varieties of the anti-tumor product line, which is expected to reach 400-600 million yuan/year sales scale.
Jiangsu Wuzhong (600200)
Jiangsu Wuzhong Pharmaceutical Group Co., Ltd., the controlling subsidiary of Jiangsu Wuzhong, and the Jiangsu Provincial Department of Science and Technology signed the "Jiangsu Provincial Scientific and Technological Achievements Transformation of the Special Funds Project Contract," the company in the study of the "national class of biological anticancer drug recombinant human vascular endothelial inhibitor injection to obtain the research and development and industrialization" project has been the Jiangsu Provincial Scientific and Technological Achievements Transformation of the special funds support. Special fund support. Data show that recombinant human vascular endothelial inhibin injection for the national class of new biological anticancer drugs, with independent intellectual property rights, in 2006 was the national "863" project support for non-small cell lung cancer. At present, the project is in the phase III clinical research stage, and the acquisition of the project funds will provide an important financial guarantee for the phase III clinical research work and future industrialization of the project.
Haixin (600851)
Haixin Biotechnology, the holding subsidiary of the company, cooperated with Shanghai Second Military Medical University to develop "antigen-sensitized human dendritic cells" (APDC), which can be used for the treatment of rectal cancer, and it is the first independently-developed therapeutic vaccine against advanced colorectal cancer approved by the State Food and Drug Administration (SFDA) in China. At present, the bowel cancer drug market is vast, just a few major countries in the anti-colorectal cancer drug market capacity of more than 1.7 billion U.S. dollars, it is estimated that the profit margin of anti-cancer drugs can reach more than 80%.
Sihuan Bio(000518)
The company's main products include a new class of anti-cancer drugs, recombinant human interleukin-2 for injection, which is used in the comprehensive treatment of kidney cancer, malignant melanoma and other malignant tumors.
Southwest Synthesis (000788):
The company cooperates with Founder Institute of Pharmaceutical Research on Compradine Disodium Phosphate (CA4P) and injection, a vascular targeting or endothelial disrupting drug.
Fosun Pharma (600196):
The company's monoclonal antibody drug project with Chemo Group, an international pharmaceutical company, to be built on Shanghai Chemo's biomedical platform will introduce four therapeutic oncology and rheumatoid monoclones.
Hai Zheng Pharmaceutical (600267)
The company's under-construction preparation export base project has an annual output of cytotoxic antitumor drug aqueous injection 25 million bottles of the company's gene drug tumor necrosis factor receptor antibody fusion protein is now in the stage of phase II clinical trials.
Zhongxin Pharmaceuticals (600323):
The company's leading product "Anfolon" - the second generation of genetically engineered α-2b interferon.
Hainan Haiyao Pharmaceutical (000566):
The company's main products include the anti-tumor drug Paclitaxel injection, which can be used to treat ovarian cancer.